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Summary Exploring the fundamental mechanisms behind the low tumour uptake of labelled monoclonal
antibodies (MoAbs) during in vivo immunotargeting, experiments were performed to estimate the in vivo value
of the association constant (Ka) in an experimental targeting reaction. An artificial tumour model was utilised,
based on diffusion chambers (DC) filled with antigen-coated polymer particles, implanted i.p. in normal,
immunocompetent mice (NMRI/BOM). The MoAb H7 with specificity for placental alkaline phosphatase
(PLALP) was chosen for this experiment. Each mouse carried two DC, one target DC filled with PLALP-
coated particles, and a second control DC with the same amount of uncoated particles. The DC contained
escalating doses of particles, ranging from 0.1 mg to 16 mg per DC, with groups of 6-12 animals per dose
level. The next day after the implantation, a constant dose of '25l-labelled Fab fragments of H7 was injected
i.v. in each mouse.
The association constant Ka as measured from the binding data obtained in vivo was not significantly
different from the value measured in vitro when the same target DC were incubated with the '25l-Fab in test
tubes. This indicates that in vivo impairment of the antibody avidity is not the reason why a relatively low
tumour uptake is generally experienced in immunotargeting studies.
With the development of the hybridoma technology for prod-
uction of monoclonal antibodies (Kohler & Milstein, 1975),
there has been an increasing interest in diagnosis and treat-
ment of cancer with labelled antibodies to tumour associated
antigens (Epenetos & Kosmas, 1989). However, for various
reasons, the tumour uptake of labelled MoAbs is disappoin-
tingly low in most targeting studies. Firstly, non-specific
binding of antibody in normal tissues is regularly
experienced. Secondly, the antibody concentration in the
tumour is lowered due to antibody catabolism and clearance.
Thirdly, various local mechanisms such as tumour vas-
culature, blood flow, tumour tissue permeability, and the
tumour interstitial pressure hampers the antibody access to
the tumour antigen (Jain, 1989; Matzku et al., 1990).
Moreover, as in every immunological reaction, the avidity
of the antibody should presumably be a factor of uttermost
importance to the tumour uptake. If the avidity is impaired
in vivo, this would contribute to the low tumour uptake. To
be able to explore this question, experimental binding data
from in vivo targeting reactions where the amounts of
antibody and antigen are under control is required. This
problem was overcome by applying the artificial tumour
model elaborated by us (Fjeld et al., 1988). The model is
based on intraperitoneal diffusion chambers (DC) filled with
a suspension of antigen-coated polymer particles. Any experi-
mental animal species large enough to carry the DC can be
utilised (Fjeld et al., 1990). With this model system it is
possible to systematically vary the antigen concentration in
the target. Each target has the same size, and measurement
of specific antibody uptake is made possible by the antigen-
negative control target carried by each animal.
The aim of the present work was to compare the in vivo
and in vitro avidity of a high avidity Fab fragment of the
MoAb H7, specific for placental alkaline phosphatase
(PLALP) (Millin & Stigbrand, 1983). The in vivo immuno-
targeting is performed with PLALP-coated DC i.p. in nor-
mal, immunocompetent mice, while the in vitro experiments
are carried out with the DC kept in test tubes with buffer,
with the labelled antibody added.
Materials and methods
Monodispersepolymerparticles coated withplacental alkaline
phosphatase (PLALP)
Hydrophilic monodisperse shell-and-core polymer particles
with diameter 3.3 gLm were used (Nustad et al., 1984a; Nus-
tad et al., 1984b), and the particles were coated with PLALP
as previously described (Fjeld et al., 1988), using PLALP
isolated from placentae at term (Nustad et al., 1984b).
The amount of PLALP on the particle surface was
quantified as enzyme activity, and as antigen for its specific
antibody H7. By determination of the enzyme activity, using
p-dinitrophenyl phosphate as substrate, the amount of
particle-bound PLALP was determined to be 32 10-10pmol
(1900 PLALP molecules) per particle (Fjeld et al., 1988). An
estimate of the binding capacity of the particles for the
'251I-labelled Fab fragment of the PLALP-specific MoAb H7
was obtained by mixing a relatively high and constant
amount of 1251-Fab with decreasing number of particles. In
dilutions close to antibody excess, the antibody uptake per
particle levelled out, and the amount of 251I-Fab bound at
this plateau level was 53 1010 pmol (3200 molecules) per
particle, or an average of 1.7 251I-Fab per PLALP molecule
on the particle surface. This corresponds with the dimeric
structure of the PLALP molecule.
Preparation ofdiffusion chambers (DC)
DC were constructed as described (Benestad & Reikvam,
1975). In short, the DC consisted of two Millipore GSWP
0.22;Lm micropore membranes (MilliporeR Corp., Bedford,
Mass) heat sealed to both sides of a 2 mm thick acrylic
plastic ring, outer diameter 13 mm. All chambers were filled
with 1601sl particle suspension from a syringe through an
orifice in the plastic ring, and closed with a conical plastic
plug. The particles were suspended in PBS with 5% normal
mouse serum and 200 ggml-' ampicillin.
Mice
Randomly bred female mice (NMRI/BOM), 8-12 weeks of
age, were used.
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DC implantation in mice
The operation was carried out under ether anaesthesia the
day before antibody injection. The DC were i.p. implanted
through a midline laparotomy, and the wounds were closed
with metal clips. Each mouse received two DC, one target
DC filled with PLALP-coated polymer particles, and a
second control DC with a corresponding number of PLALP-
free particles.
Antibody
The antibody was a Fab fragment of the MoAb H7 (IgG2a,
kappa), specific for the three common allelic variants of
PLALP and most types of testis PLALP-like enzymes
(Milla'n & Stigbrand, 1983). Fab fragments were prepared as
described earlier (Fjeld et al., 1988).
Radiolabelling with 125I
The Fab fragments were labelled with 125I, using Iodo-Gen
(Pierce, Rockford, Illinois) as oxidant (Fraker & Speck, 1978;
Paus et al., 1982). The iodination procedure was carried out
the day before i.v. injection.
Antibody injection
The '251I-Fab was diluted in 0.9% NaCl with 0.1% normal
mouse serum. The next day after the DC implantation, the
mice were injected i.v. (tail vein) with 100 ng '25I-Fab in
200ftl.
Harvest ofthe intraperitoneal DC
The two DC carried by each animal, i.e. one DC with the
antigen-coated particles and a second control DC, were col-
lected from animals killed by ether overdosage. The DC were
immediately removed, gently wiped off with a piece of soft
paper, and the radioactivity in the whole DC was counted in
a multiwell gamma counter. The specific binding to the
antigen-coated particles was obtained from the difference in
radioactivity between the target and control DC.
DC incubated in vitro in test tubes
The '25I-Fab uptake in DC in vitro was measured using test
tubes with 7 ml PBS with 1% BSA and 0.01% NaN3. Each
test tube contained one target DC and a second control DC,
25I-FAb was added (0.3 ng 50pl-'), and the tubes were
rotated end over end at 37°C. As in the animal experiments,
the target and control DC were gently wiped off with soft
paper, the radioactivity in the whole DC were counted, and
the specific uptake was measured as the difference between
the target and control DC.
Theoretical backgroundfor the in vivo parameter estimation
Presuming that the targeting reaction between the '25I-Fab
and its binding sites on the PLALP-coated particles is a
bimolecular and reversible reaction, and that both the reac-
tants have homogeneous binding characteristics, the reaction
will obey the first order form of the mass action law. Then,
as previously described for labelled MoAb - antigen reactions
in general (Fjeld & Skretting, 1992), simple rearrangement of
the mass action law gives the following model equation for
the reaction at equilibrium:
B(i) = (A-(A2-C)05)/D (I)
Adaption of equation I to the DC model system for RIT
gives the following definitions:
A
C
D
N
= 1 + Ka-FT + Ka-N-M(i)
= 4-Ka2N F-M(i)-T
= 2 Ka-M(i)
= Total number of effective binding sites per polymer
particle
B(i) = Number of specifically bound "25I-Fab molecules per
polymer particle within a specified DC
T = The dose of '25I-Fab injected i.v.
M(i) = Concentration of PLALP-coated polymer particles
within a specified DC
F = The maximal fraction of injected dose of '251I-Fab
that is bound to the target particles in the DC,
when the concentration of effective binding sites on
the PLALP-coated particles is in extreme excess
relative to the concentration of the '25I-Fab
molecules available.
Equation I has three unknown parameters Ka, F and N.
The constant antibody dose T and the systematically varied
concentration of particles M(i) in the target DC are chosen
values, whereas B(i) is the experimentally measured specific
antibody uptake in the target DC. With three unknown
parameters and only one equation, an iterative nonlinear
least squares approximation method was used to obtain the
optimally fitting binding parameters (Fjeld & Skretting,
1992).
The parameter F is analogous to the immunoreactive frac-
tion of the labelled antibody preparation. To use the expres-
sion 'immunoreactive fraction' for the parameter F in vivo is
however somewhat misleading, because the major reason for
non-reactivity in vivo is excretion and catabolism of the i.v.
injected antibody molecules, before they become available for
the target antigen. Only the local concentration of antibody
molecules within the DC shall be taken into account in the
parameter calculations. Consequently, to be able to estimate
antibody binding parameters from data measured in vivo, the
following problem must be solved: How large a fraction of
the injected antibody dose is actually presented to the tumour
antigens? The sum of all of the different processes that affect
this fraction, such as extravasation, excretion, catabolism,
and diffusion across the DC wall, may not be a linear
function of the injected dose, and then the parameter F
defined above will vary with the injected dose. This was
solved by injecting the constant dose T of 251I-Fab to all the
animals. The parameter F should then also have a constant
value, except for the biological and random experimental
variation from animal to animal.
Results
The kinetics ofantibody uptake in the i.p. DC
Immunological binding parameters characterise the antigen-
antibody reaction under equilibrium conditions. As an intro-
ductory experiment, exploring if our in vivo targeting reaction
was close to equilibrium, a dynamic study of the target
uptake of the '25I-Fab preparation was carried out. In this
experimental set-up the particle concentration in the i.p.
target DC and the dose of antibody injected i.v. were kept
constant, while the time interval between injection and target
harvest was varied (Figure 1).
The antibody concentration in the control DC (Figure 1,
upper curve), reflecting the concentration of free antibody
within the target, increased rapidly and reached its maximum
about 3 h after the i.v. injection. This rapid increase was
followed by a period with rapid decrease towards a low
background level, giving a relatively sharp peak in the con-
centration of free, available antibodies within the DC. This
indicates a rapid extravasation and a good access to the
target for this fragmented antibody, followed by a rapid
excretion.
The specific uptake in the target DC (Figure 1, lower
curve) did also increase immediately after the injection. The
increase rate was however somewhat lower than for the free
antibody concentration, and the maximum specific uptake
was reached about 5 h after injection. In the following period
the amount of specifically bound radioactivity decreased
slowly.
From these results, a 24 h interval between injection and
tumour harvest was chosen for the consecutive series of76 J.G. FJELD et al.
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Figure 1 The kinetics of the nonspecific (upper curve) and
specific uptake (lower curve) of "5I-Fab fragments of the MoAb
H7, when administered i.v. to mice carrying i.p. implanted DC.
The DC contained 0.1 mg PLALP-coated particles in 160 1I
buffer (target DC), or the same amount of PLALP-free control
particles (control DC). Each mouse was implanted i.p. with one
target DC and one control DC, and the next day after the
operation the mice were injected i.v. (tail vein) with "1I-Fab
(100 ng 200ILI`; 7 x 106 c.p.m.). The upper curve includes all
radioactivity in the control DC, and this curve reflects therefore
the variation in i.p. concentration of free 'I5I-Fab. The specific
uptake in the target DC have been corrected for the uptake in the
neighbouring control DC. Results from single DC.
experiments, carried out to obtain binding data for the bin-
ding parameter estimation. After 24 h the specific uptake had
levelled out, i.e. the reaction had apparently reached equili-
brium, and the concentration of free antibodies had reached
a low background level.
The signal to noise ratio of the data in Figure 1 is poor.
However, the antigen concentration was low. The concentra-
tion of particles (0.1 mg 160 1 1-) in this study of the kinetics
of the antibody uptake was chosen to be in the lower part of
the range of particle concentrations planned to be used in the
consecutive study carried out to obtain data for calculation
of the immunological binding parameters for an in vivo
immunological reaction. The rationale for choosing this low
antigen level in the introductory kinetic study, was that if the
targeting reaction with the lowest particle concentration
(0.1 mg 160I1-1) in the DC is close to equilibrium, then the
reactions between the same dose of antibody and higher
particle concentrations will also be close to equilibrium. The
DC components, and not the particles, are responsible for
the nonspecific binding. The signal to noise ratio in this
model system has been explored in a previous work (Fjeld et
al., 1988).
In vivo antibody uptake vs escalating dose ofparticles in the
i.p. target DC
To obtain targeting data for calculation of immunological
binding parameters of the targeting reaction, a constant dose
of labelled antibody (100 ng 200 .l1-') was injected i.v. in
mice carrying i.p. DC with serial dilutions of particles rang-
ing from 0.1 mg 160lp' to 16mg 160It1-'. The specific
uptake increased with increasing concentration of particles,
reaching a plateau level of about 0.25% of injected antibody
dose (Figure 2, lower curve). This represents the fraction of
injected dose that is bound when the particle concentration in
the DC is in relative excess. Thus, the plateau level is close to
the value of the parameter F.
The signal to noise ratio in this experiment increased from
a poor level of 1 with 0.1 mg particles, to a ratio of 4 with
16 mg particles.
Exploring the sensitivity in this targeting system, experi-
ments were also carried out with mice carrying DC with
extremely low antigen content: 0.03 mg, 0.05 mg and 0.07 mg
particles. Each DC gave a specific uptake significantly
different from zero, and the uptake results were ranged ac-
cording to their antigen content, indicating that this is a
reliable system for studying antibody-antigen reactions in
vivo. The explanation probably is that each animal carry a
second control DC, reducing the effect of the biological and
experimental variation on the specific uptake. These data,
representing very low percentages of the injected dose bound,
were however not included in the parameter calculation pro-
cedure. The mathematical model underlying the parameter
estimation, i.e. the first order mass action law, assumes that
both the antigen and the antibody have homogeneous bin-
ding characteristics. There may be heterogeneity in the
avidity of labelled MoAbs (Matzku et al., 1985; Fjeld &
Skretting, 1992). Then, results from DC with very low
antigen content will be dominated by the antibody molecules
with the highest avidity. To reduce this problem when
estimating the parameters, the data included in the estima-
tion procedure were restricted to the results from DC with a
range of particles between 0.1 mg and 16 mg.
25
_ DC in test tubes
20-
V
o 15
-10
Xn 5-
IL
0.
.- 0.4-
0
a)
0
Q0
-0 -Fo 0-3-
0 4--
o 0.2-
0
LL
0 5 10 15
Weight of particles in DC (mg)
Figure 2 In vitro and in vivo binding of 251I-Fab to PLALP-
coated polymer particles in DC. Upper curve: DC kept at 37°C in
vitro in test tubes with 7 ml buffer for 24 h, rotated end over end.
Results from DC containing from 0.1 mg to 16 mg particles.
Lower curve: i.p. DC in mice, harvested 24 h after i.v. injection
of antibody. The antibody dose was 0.3 ng "5I-Fab (50gd) in the
test tubes, added at time 0, while 100 ng (200 Al) were
administered i.v. (tail vein) in the mice. Results from DC contain-
ing from 0.03 mg to 16 mg particles. Median values for three
replicates in vitro, and six replicates in vivo.ANTIBODY AVIDITY IN VIVO 77
In vitro antibody uptake vs escalating dose ofparticles in
target DC in test tubes
DC were filled with PLALP-coated polymer particles, or
control particles. We tried to make the in vitro experimental
conditions as close to the in vivo situation as possible. Thus,
the incubation temperature was 37°C, the buffer volume in
the test tubes was 7 ml which should be close to the distribu-
tion volume of an i.v. injected antibody in mice (Fjeld et al.,
1991), and the amount of antibody added was reduced to
0.3 ng to obtain an available antibody concentration similar
to the in vivo situation. This low dose was chosen on the
basis of the measured level of antibody in the blood and in
the i.p. DC. The incubation time was 24 h. The antibody
fraction specifically bound to the PLALP-coated particles in
the DC increased with increasing amount of particles,
reaching a plateau of about 20% when the reaction was close
to relative antigen excess (Figure 2, upper curve). This frac-
tion of bound antibody was about 75 times higher than
obtained in vivo.
The similarity in the shape of the two binding curves
(Figure 2) indicates that the avidity of this labelled antibody
is about the same in vitro and in vivo. This was confirmed by
the estimated parameter values presented below.
Estimation ofbinding parameters
When estimating the antibody association constant (Ka) of
the labelled antibody, the number of effective binding sites
(N) per target particle, and the fraction of injected (or added)
dose (F) bound at infinite antigen excess in the target are
needed. For a labelled antibody, these three parameters are
interdependent parameters in the law of mass action. A
computerised nonlinear least squares fitting procedures (Fjeld
& Skretting, 1992) was applied to estimate the parameter
values that give optimal fitness of the experimental data with
the mathematical model derived from the first order mass
action law, as described in Materials and methods. This
estimation procedure was carried out with both the in vivo
and the in vitro experimental data. The in vivo estimated
values for Ka and N corresponded fairly well with the in
vitro estimates, while the estimated value for F was definitely
lower in vivo than in vitro (Table I). This discrepancy reflects
the fact that catabolism and renal excretion decrease the
amount of antibody presented to the target DC in vivo.
For legitimate comparison of antibodies used in different
assays, the same range of antigen-binding antibody domains
must be employed in the assays (Steward, 1986; Fjeld &
Skretting, 1992). The explanation is that most antigen-
antibody reactions are somewhat heterogenic, such that the
parameter estimates may be affected by the range of experi-
mental data included in the model fitting procedure. That a
comparative range of data were obtained is seen directly
from Figure 2. Moreover, when using the estimated F values
to calculate the total amount of immunoreactive antibodies
available, between 19% and 100% were bound in vivo in DC
containing between 0.1 mg and 16 mg particles, and between
26% and 100% in vitro. Thus, the data sets were comparable
with respect to the fraction of bound binding sites of the
antibodies, and therefore comparison of the antibody avidity
as calculated in vivo and in vitro is legitimate.
Discussion
The rationale for estimating immunological binding para-
meters from in vivo experimental binding data, was to explore
the basic problem of insufficient antibody uptake in
immunotargeting. Theoretically, the tumour uptake of the
labelled antibody may be impaired for reasons such as in vivo
proteolytic degradation or complexing with other molecules,
giving conformational changes that reduce the antibody
avidity. Alternatively, an in vivo all or none process may
destroy the antibody affinity. This would however not affect
the Ka, but only reduce the F value.
To our knowledge, the question of reduced avidity has not
been explored before, presumably because systematic varia-
tion of antigen-antibody dilutions are difficult in vivo. How-
ever, with the artificial targeting model here applied, we were
able to design an intraperitoneal binding assay, and the
results obtained indicate that the association constant of the
fraction of antibodies reacting with the target was not
significantly changed in vivo. However, if processes specific
for the tumour tissues are responsible for reduction in the
avidity of injected MoAbs, this phenomenon is not observed
with the DC model.
In the mathematical model applied, deduced by simple
rearrangement of the first order form of the law of mass
action, it is assumed that the antibody-antigen reaction has
reached equilibrium. The specific uptake of antibody in the
i.p. DC levelled out after 5 h, indicating that equilibrium
conditions were reached. The width of the concentration
peak of free antibody concentration in the DC indicate that
the effective period of antibody uptake lasted for a relatively
short period in vivo, i.e. about 2-3 h. From our experience
with this antibody in vitro, this period of time is enough to
achieve an equilibrium situation. This concentration level of
antibodies reaching the i.p. DC liquid mimics an in vitro
situation with antibody incubation, followed by a washing
procedure. However, there is nevertheless an unavoidable
discrepancy between the concentration profile of free
antibodies in vivo and in vitro.
In the period after the specific uptake had reached its
maximum, there was a continuous decline in the specifically
bound radioactivity in vivo. This could be due to leakage of
antigen from the particles, loss of label from the antibody,
and antibody dissociation due to equilibrium readjustment to
the continuously decreasing concentration of free antibodies.
TableI Thebindingparameters ofthe'25I-FAbvsPLALP-coated particlescontained in DC,
as determined in vitro and in vivo
Ka x 10-9 F N Correlation between experimental
(I moV') (%) (particle-') and calculatedparticle uptake
In test tubes 1.65 20 3290 y = 0.97x + 0.17, r = 0.998
I.p. in mice 1.40 0.26 2870 y = 0.89x + 2.93, r = 0.990
Ka: Theassociation constant, F: Thisparameter hasdifferentmeanings in vitro and in vivo.
Inthetest tubeexperiments this is theimmunoreactive fraction ofthe '25I-Fabpreparation. In
the mouse experiments F is the fraction ofthe injected dose bound at infinite antigen excess
within the target DC, and therefore equal to the product ofthe immunoreactive fraction as
measured in vitro and the fraction ofinjected dose available to the antigen after catabolism
and clearance. N: Number of effective binding sites on the particles.
The linear least squares fitting function y = ax + b and the correlation coefficient r reflect
thecorrespondencebetweentheexperimentallymeasured uptake (x)of'25I-Fabmoleculesper
particle, and the uptake (y) calculated when substituting the estimated parameters into
equation I, derived from the first order law of mass action.78 J.G. FJELD et al.
Previous experiments have confirmed that there is a slow
antigen shedding from the particles, and that the total loss
rate due to antigen shedding and dehalogenation is the same
in vivo and in vitro in this model system (Fjeld et al., 1988).
We have measured a slow antibody dissociation from the
particles in vivo when the concentration of free antibodies
was zero, but also this phenomenon occurred with the same
rate in vitro (Fjeld et al., unpublished). Hence, a somewhat
higher antibody dissociation may occur in vivo because the
i.p. concentration of free antibodies decreased rapidly due to
renal excretion. This might contribute to the minor disc-
repancies between the in vitro and in vivo values for Ka.
The parameters estimated from in vivo data did slightly
underestimate the target uptake, except for very low uptake
values (Table I). This downward scew of the correlation line
obtained with the in vivo values is difficult to explain.
Irrespective of the methodological problems concerning the
binding parameter calculations, similar antibody avidity in
vitro and in vivo is indicated directly from the similarity of
the two binding curves in Figure 2, because the target antigen
load is identical in vitro and in vivo. Therefore, the conclusion
can be drawn that the low antibody uptake experienced in
the present immunotargeting study is mainly a consequence
of the fact that a low fraction F of the injected dose becomes
available to the target antigen, and not due to impaired
antibody avidity in vivo.
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